Activin A–Activated ALK4 Induces Pathogenic Th17‐Involved Endothelial–Mesenchymal Transition in Systemic Lupus Erythematosus–Associated Pulmonary Arterial Hypertension
Arthritis & Rheumatology · 2025
DOI: 10.1002/art.43235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Shuliang Jing und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Department of Cardiology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Activins, Th17 Cells, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, the National Fundation Science of China, Beijing Nova Program.
Abstract (Originalsprache)
Objective
Autoimmune diseases, such as systemic lupus erythematosus (SLE), are associated with pulmonary arterial hypertension (PAH), a condition that can lead to heart failure. However, whether T cells also contribute to the occurrence of PAH in SLE has not been clarified. The objective of this study was to elucidate the role of Activin A and activated receptor signaling in SLE‐PAH.
Methods
Mass Cytometry (CyTOF) analysis was performed to identify the major affected immune cell population in patients with SLE‐PAH. Serum Activin A and interleukin‐17 (IL‐17) levels in patients with SLE‐PAH, patients with SLE, and healthy donors were determined by enzyme‐linked immunosorbent assay. Cocultures of Th17 cells with pulmonary microvascular endothelial cells (PMECs) and relevant rodent models were used to identify the converged target.
Results
The reduced CD4 + T cell number was detected in patients with SLE‐PAH after treatment with immunosuppressant and vasodilator. Increased Th17 cells population and higher serum Activin A and IL‐17 levels were found in patients with SLE‐PAH compared to patients with SLE only or donors. Activin A signals via activin receptor–like kinase 4 (ALK4) in both Th17 cells and PMECs. Overexpressing ALK4 in Th17 cells increased IL‐6 and endothelial–mesenchymal transition (EndoMT) marker levels in cocultured PMECs. We found severe SLE–pulmonary hypertension (PH) in mice by overexpressing ALK4, and alleviated hemodynamic changes in CD4 + T cells depletion mice. ALK4 inhibitor vactosertib (TEW‐7197) effectively treated SLE‐PH mice by repressing connective tissue growth factor ( CTGF ) transcription, which was induced by ALK4 activated pSmad2 and pSTAT3.
Conclusion
Our findings suggest that Activin A activates ALK4 in Th17 cells, thereby inducing IL‐17 secretion. Concurrently, activated ALK4 induces EndoMT in human PMECs (hPMECs) via CTGF up‐regulation. It suggests that ALK4 is a promising therapeutic target for SLE‐PAH. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Department of Cardiology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China.
- Stem Cell Facility of National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union College, Beijing, Ch…
- Department of Pulmonary Medicine, Amsterdam University Medical Center Vrije University, Amsterdam, The Netherlands.
- Department of Immunology, School of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Physiology, and Department of Cardiology of the Second Affiliated Hospital, Zhejiang University School of Medicine and State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China.
ORCID-Profile: Junyan Qian, Mengtao Li, Jun Yang
Förderung
- National Key Research and Development Program of China
- the National Fundation Science of China
- Beijing Nova Program
Zitieren
APA
Jing, S., Qian, J., Ying, H., Mao, P., Yao, M., Wu, Z., Bogaard, H. J., Wang, L., Li, M., & Yang, J. (2025). Activin A–Activated ALK4 Induces Pathogenic Th17‐Involved Endothelial–Mesenchymal Transition in Systemic Lupus Erythematosus–Associated Pulmonary Arterial Hypertension. Arthritis & Rheumatology. https://doi.org/10.1002/art.43235
Vancouver
Jing S, Qian J, Ying H, Mao P, Yao M, Wu Z, et al. Activin A–Activated ALK4 Induces Pathogenic Th17‐Involved Endothelial–Mesenchymal Transition in Systemic Lupus Erythematosus–Associated Pulmonary Arterial Hypertension. Arthritis & Rheumatology. 2025. doi:10.1002/art.43235
BibTeX
@article{Jing2025,
author = {Jing, Shuliang and Qian, Junyan and Ying, Hongjie and Mao, Pei and Yao, Mingxin and Wu, Zhihong and Bogaard, Harm J and Wang, Lie and Li, Mengtao and Yang, Jun},
title = {Activin A–Activated ALK4 Induces Pathogenic Th17‐Involved Endothelial–Mesenchymal Transition in Systemic Lupus Erythematosus–Associated Pulmonary Arterial Hypertension},
journal = {Arthritis & Rheumatology},
year = {2025},
doi = {10.1002/art.43235}
}
EUVIMED